Skip to content
2000
Volume 5, Issue 3
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Atherosclerotic coronary artery disease remains a major healthcare concern especially in developed countries. While lowering plasma cholesterol levels via diet, exercise, and pharmacoptherapy can reduce this risk of developing coronary artery disease, there remains a need for more effective drug therapies. The azetidinone cholesterol absorption inhibitors typified by ezetimibe represent the first new approach to lipid lowering therapy in more than a decade. This review summarizes the medicinal chemistry of the azetidinone cholesterol absorption inhibitors as a class, with emphasis on factors that contributed both to the discovery of ezetimibe as well as to our overall understanding of S.A.R. trends in this area.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026053544498
2005-04-01
2025-05-08
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026053544498
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test